The incidence of lung cancer diagnosed in the elderly population is rising as a result of increasing life expectancy. Patients aged over 65 years at diagnosis represent half of the population newly diagnosed with non-small cell lung cancer (NSCLC), while 30-40 % of cases are diagnosed in patients older than 70 years.
70 years is considered to be the reference point in clinical trials. The age-related physiological changes that increase the risk of toxicity related to systemic therapy occur around 70 years of age. 2 Extermann et al. have defined the geriatric oncology group of patients as "when the health status of a patient population begins to interfere with oncological decision-making guidelines". 3 Within clinical trials, this is defined by exclusion criteria and, as pointed out in the review by Pallis et al., a number of barriers (other than comorbid conditions) to the recruitment of older patients to cancer clinical trials have been revealed, 4 such as difficulty in accessing university hospitals, lack of adequate information about the availability of clinical trials, and perception of the individual physician that the patient would not be able to tolerate treatment. The conclusion of a prospective, population-based trial by
De Ruysscher et al. on eligibility for concurrent chemoradiation (CCRT) concluded that more than half of patients with LA-NSCLC were theoretically not eligible because they had one or more important comorbid conditions or were 75 years or older. 5 Consequently, prospective elderly-specific trials are lacking and treatment recommendations are made on the basis of retrospective data. These might suffer from selection bias, since elderly patients who meet protocol eligibility criteria often do not present with comorbid conditions or organ function failures that present in the real-life situation. Because of the rising incidence of NSCLC in the elderly population, biological age rather than chronological age should guide clinicians in deciding on treatment strategy. Geriatric scoring systems can be implemented in an attempt to better define the role of comorbid disease in the elderly population. In addition, technological advances in the field of radiotherapy could contribute to increased efficacy 6 and reduced side effects 7 of treatment in the LA-NSCLC patient population.
Available Evidence Supporting Concurrent Chemoradiation in the Elderly Population
Regarding the use of radiotherapy in elderly patients, it has been reported that elderly patients are not at risk of increased acute or late toxicity after radiotherapy with curative doses. 8, 9 The addition of chemotherapy to radiation has an additional effect on survival in LA-NSCLC at the price of increased toxicity. 10 Concurrent chemoradiation (CCRT) has a temporary impact on quality of life, primarily because of fatigue and esophagitis during and shortly after treatment. However, the quality of life usually recovers to baseline values within three months. Because of the small number of patients included and protocol violations concerning the radiation field that might have influenced half of the treatment-related deaths attributed to pneumonitis, the investigators concluded that the efficacy of concurrent carboplatin plus radiotherapy in elderly patients remains unclear and no definitive conclusions can be drawn from this trial.
When looking at retrospective subgroup analyses of randomised chemoradiation trials comparing treatment outcomes between elderly and younger patients, results are inconsistent (see Table 1 ). The secondary analysis of a Radiation Therapy Oncology Group (RTOG) study demonstrated inferior outcomes of chemoradiation in the elderly and those with poorer performance status. 16 Movsas et al. reported that the best quality-adjusted survival in older patients was achieved with RT alone. 17 In contrast, subset analyses of several other trials 14, [18] [19] [20] and the NSCLC Collaborative Group meta-analysis 21 concluded that the survival advantage of chemoradiation was not related to age. 
Concurrent Chemoradiation in the Frail Elderly
We could only identify one institutional report, by Semrau et al., on CCRT in elderly LA-NSCLC patients presenting with multiple morbidities. 23 The authors reported on their six-year experience of CCRT with vinorelbine plus a platinum compound. The frail elderly population was defined as patients with an increased risk profile of treatment side effects due to World Health Organization (WHO) performance status 2-3, cardiac, renal or pulmonary failure, extensive weight loss before treatment, or age 71-78 years. A total of 66 patients received CCRT, with manageable toxicity. The dose intensity of chemotherapy and radiotherapy was 62 % and 94 %, respectively. In this population with poor prognostic factors, dose-adjusted chemotherapy and radiotherapy was feasible, and the survival rates of 25 % at two years and 8 % at five years were comparable to those achieved in other studies.
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Technological Advances in the Field of Radiotherapy
Technological advances in radiotherapy treatment planning and delivery have occurred in the past five years, including incorporation Our group has engaged in a Phase I/II radiation dose escalation trial using helical tomotherapy with a fixed low-dose of weekly chemotherapy consisting of cisplatin and docetaxel at a dose of 20 mg/m 2 each. The toxicity profile of this approach has been published earlier. 24 We thereafter compared treatment-related toxicity, impact of treatment on quality of life, and differences in outcome between younger (<70 years, n=42) and older (≥70 years, n=17) patients. Besides an increased rate of neutropenia, elderly patients did not experience increased toxicity or decreased quality of life after concurrent chemoradiation. A comparable survival was achieved, with a median survival time of 18.5 months in the younger versus 17.9 months in the older patient group (p=0.6105).
Comprehensive Geriatric Assessment-based Approach
The current standard of functional status assessment using Eastern 26 There is strong evidence that a CGA detects problems that may have been missed by a regular clinical evaluation.
Accumulating data show the benefit of incorporating a CGA in the initial evaluation of older patients with cancer, because it uncovers problems relevant to cancer care that would otherwise go unrecognized and can predict morbidity and mortality in older patients with cancer.
Pre-treatment values of instrumental activities of daily living correlate with survival. 3 Therefore, the integration of geriatric assessment into studies with a high proportion of older patients needs to be encouraged.
Conclusions
Concurrent chemoradiation should be offered to elderly patients suffering from LA-NSCLC, since a survival benefit can be achieved. Even in the absence of prospective elderly-specific data, we encourage treatment of older patients with CCRT since elderly patients treated with CCRT outside the clinical trial setting experience the same survival benefit-albeit with a shorter survival duration. Elderly-specific CCRT trials incorporating modern radiation techniques and geriatric assessment should be encouraged to truly establish the place of CCRT in the older patient with LA-NSCLC. n
